Gyre Therapeutics, Inc.
GYRE
$7.64
$0.060.79%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 19.92% | 6.13% | -18.82% | 2.67% | -20.45% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 19.92% | 6.13% | -18.82% | 2.67% | -20.45% |
| Cost of Revenue | 69.94% | 49.48% | -8.68% | -5.84% | -19.09% |
| Gross Profit | 17.96% | 4.76% | -19.20% | 3.08% | -20.51% |
| SG&A Expenses | 12.13% | 12.25% | -0.90% | -15.83% | 16.16% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.21% | 12.00% | 3.58% | -15.86% | 10.26% |
| Operating Income | 63.62% | -33.42% | -71.84% | 112.78% | -66.84% |
| Income Before Tax | 94.12% | -62.92% | -62.86% | 100.77% | -64.87% |
| Income Tax Expenses | 57.64% | -55.78% | -64.61% | -70.96% | -70.80% |
| Earnings from Continuing Operations | 107.84% | -65.27% | -62.42% | 100.56% | -61.97% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -34.30% | -12.28% | 56.89% | -2,203.45% | 50.99% |
| Net Income | 221.17% | -87.47% | -64.18% | 99.90% | -71.73% |
| EBIT | 63.62% | -33.42% | -71.84% | 112.78% | -66.84% |
| EBITDA | 61.93% | -19.40% | -66.91% | 123.23% | -63.92% |
| EPS Basic | 203.05% | -87.89% | -65.52% | 99.91% | -79.04% |
| Normalized Basic EPS | 216.47% | -90.85% | -66.82% | 97.81% | -85.74% |
| EPS Diluted | 166.41% | -63.33% | -86.39% | 99.76% | -73.80% |
| Normalized Diluted EPS | 230.99% | -90.51% | -65.40% | 97.81% | -85.21% |
| Average Basic Shares Outstanding | 6.08% | 4.23% | 3.79% | 18.45% | 34.68% |
| Average Diluted Shares Outstanding | 1.30% | 0.49% | -0.61% | 18.45% | 30.08% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |